Cargando…

Geographical concentration of falciparum malaria treated in the UK and delay to treatment with artesunate in severe cases: an observational study

OBJECTIVES: To quantify geographical concentration of falciparum malaria cases in the UK at a hospital level. To assess potential delay-to-treatment associated with hub-and-spoke distribution of artesunate in severe cases. DESIGN: Observational study using national and hospital data. SETTING AND PAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Broderick, Claire, Friend, Philip, Smith, Valerie, Blaze, Marie, Gothard, Philip, Chiodini, Peter L, Whitty, Christopher JM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533059/
https://www.ncbi.nlm.nih.gov/pubmed/23148346
http://dx.doi.org/10.1136/bmjopen-2012-001854
_version_ 1782254385130110976
author Broderick, Claire
Friend, Philip
Smith, Valerie
Blaze, Marie
Gothard, Philip
Chiodini, Peter L
Whitty, Christopher JM
author_facet Broderick, Claire
Friend, Philip
Smith, Valerie
Blaze, Marie
Gothard, Philip
Chiodini, Peter L
Whitty, Christopher JM
author_sort Broderick, Claire
collection PubMed
description OBJECTIVES: To quantify geographical concentration of falciparum malaria cases in the UK at a hospital level. To assess potential delay-to-treatment associated with hub-and-spoke distribution of artesunate in severe cases. DESIGN: Observational study using national and hospital data. SETTING AND PARTICIPANTS: 3520 patients notified to the Malaria Reference Laboratory 2008–2010, 34 patients treated with intravenous artesunate from a tropical diseases centre 2002–2010. MAIN OUTCOME MEASURES: Geographical location of falciparum cases notified in the UK. Diagnosis-to-treatment times for intravenous artesunate. RESULTS: Eight centres accounted for 43.9% of the UK's total cases; notifications from 107 centres accounted for 10.2% of cases; 51.5% of hospitals seeing malaria notified 5 or fewer cases in 3 years. Centres that saw <10 cases/year treat 26.3% of malaria cases; 6.1% of cases are treated in hospitals seeing <2 cases/year. Concentration of falciparum malaria was highest in Greater London (1925, 54.7%), South East (515, 14.6%), East of England (402, 11.4%) and North West (192, 5.4%). The North East and Northern Ireland each notified 5 or fewer cases per year. Median diagnosis-to-treatment time was 1 h (range 0.5–5) for patients receiving artesunate in the specialist centre; 7.5 h (range 4–26) for patients receiving it in referring hospitals via the hub-and-spoke system (p=0.02); 25 h (range 9–45) for patients receiving it on transfer to the regional centre from a referring hospital (p=0.002). CONCLUSIONS: Most UK hospitals see few cases of falciparum malaria and geographical distances are significant. Over 25% of cases are seen in hospitals where malaria is rare, although 60% are seen in hospitals seeing over 50 cases over 3 years. A hub-and-spoke system minimises drug wastage and ensures availability in centres seeing most cases but is associated with treatment delays elsewhere. As with all observational studies, there are limitations, which are discussed.
format Online
Article
Text
id pubmed-3533059
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-35330592013-01-04 Geographical concentration of falciparum malaria treated in the UK and delay to treatment with artesunate in severe cases: an observational study Broderick, Claire Friend, Philip Smith, Valerie Blaze, Marie Gothard, Philip Chiodini, Peter L Whitty, Christopher JM BMJ Open Infectious Diseases OBJECTIVES: To quantify geographical concentration of falciparum malaria cases in the UK at a hospital level. To assess potential delay-to-treatment associated with hub-and-spoke distribution of artesunate in severe cases. DESIGN: Observational study using national and hospital data. SETTING AND PARTICIPANTS: 3520 patients notified to the Malaria Reference Laboratory 2008–2010, 34 patients treated with intravenous artesunate from a tropical diseases centre 2002–2010. MAIN OUTCOME MEASURES: Geographical location of falciparum cases notified in the UK. Diagnosis-to-treatment times for intravenous artesunate. RESULTS: Eight centres accounted for 43.9% of the UK's total cases; notifications from 107 centres accounted for 10.2% of cases; 51.5% of hospitals seeing malaria notified 5 or fewer cases in 3 years. Centres that saw <10 cases/year treat 26.3% of malaria cases; 6.1% of cases are treated in hospitals seeing <2 cases/year. Concentration of falciparum malaria was highest in Greater London (1925, 54.7%), South East (515, 14.6%), East of England (402, 11.4%) and North West (192, 5.4%). The North East and Northern Ireland each notified 5 or fewer cases per year. Median diagnosis-to-treatment time was 1 h (range 0.5–5) for patients receiving artesunate in the specialist centre; 7.5 h (range 4–26) for patients receiving it in referring hospitals via the hub-and-spoke system (p=0.02); 25 h (range 9–45) for patients receiving it on transfer to the regional centre from a referring hospital (p=0.002). CONCLUSIONS: Most UK hospitals see few cases of falciparum malaria and geographical distances are significant. Over 25% of cases are seen in hospitals where malaria is rare, although 60% are seen in hospitals seeing over 50 cases over 3 years. A hub-and-spoke system minimises drug wastage and ensures availability in centres seeing most cases but is associated with treatment delays elsewhere. As with all observational studies, there are limitations, which are discussed. BMJ Publishing Group 2012-11-12 /pmc/articles/PMC3533059/ /pubmed/23148346 http://dx.doi.org/10.1136/bmjopen-2012-001854 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Infectious Diseases
Broderick, Claire
Friend, Philip
Smith, Valerie
Blaze, Marie
Gothard, Philip
Chiodini, Peter L
Whitty, Christopher JM
Geographical concentration of falciparum malaria treated in the UK and delay to treatment with artesunate in severe cases: an observational study
title Geographical concentration of falciparum malaria treated in the UK and delay to treatment with artesunate in severe cases: an observational study
title_full Geographical concentration of falciparum malaria treated in the UK and delay to treatment with artesunate in severe cases: an observational study
title_fullStr Geographical concentration of falciparum malaria treated in the UK and delay to treatment with artesunate in severe cases: an observational study
title_full_unstemmed Geographical concentration of falciparum malaria treated in the UK and delay to treatment with artesunate in severe cases: an observational study
title_short Geographical concentration of falciparum malaria treated in the UK and delay to treatment with artesunate in severe cases: an observational study
title_sort geographical concentration of falciparum malaria treated in the uk and delay to treatment with artesunate in severe cases: an observational study
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533059/
https://www.ncbi.nlm.nih.gov/pubmed/23148346
http://dx.doi.org/10.1136/bmjopen-2012-001854
work_keys_str_mv AT broderickclaire geographicalconcentrationoffalciparummalariatreatedintheukanddelaytotreatmentwithartesunateinseverecasesanobservationalstudy
AT friendphilip geographicalconcentrationoffalciparummalariatreatedintheukanddelaytotreatmentwithartesunateinseverecasesanobservationalstudy
AT smithvalerie geographicalconcentrationoffalciparummalariatreatedintheukanddelaytotreatmentwithartesunateinseverecasesanobservationalstudy
AT blazemarie geographicalconcentrationoffalciparummalariatreatedintheukanddelaytotreatmentwithartesunateinseverecasesanobservationalstudy
AT gothardphilip geographicalconcentrationoffalciparummalariatreatedintheukanddelaytotreatmentwithartesunateinseverecasesanobservationalstudy
AT chiodinipeterl geographicalconcentrationoffalciparummalariatreatedintheukanddelaytotreatmentwithartesunateinseverecasesanobservationalstudy
AT whittychristopherjm geographicalconcentrationoffalciparummalariatreatedintheukanddelaytotreatmentwithartesunateinseverecasesanobservationalstudy